Lit­tle De­ci­phera will hus­tle pos­i­tive PhI­II sur­vival da­ta on lead can­cer drug to the FDA in search of its first OK — shares soar

De­ci­phera has spent the last 5 years po­si­tion­ing it­self as an­oth­er com­mer­cial play­er-to-be in the hec­tic on­col­o­gy are­na, steer­ing its way through a $127 mil­lion IPO $DCPH in 2017, hir­ing Pfiz­er vet Mike Tay­lor as CEO — and then re­plac­ing him with some­one with mar­ket­ing ex­pe­ri­ence last spring.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER